Meselu Belsity Temesgen, Demelie Birhanu Barud, Shedie Tigist Adeb
Midwifery Department, Debre Markos University, Debremarkos, Amhara, Ethiopia.
Amhara Development Association, Debremarkos, Amhara, Ethiopia.
Tuberc Res Treat. 2022 Mar 31;2022:6325633. doi: 10.1155/2022/6325633. eCollection 2022.
Ethiopia is one of the highest tuberculosis burden countries globally, and tuberculosis is one of the most pressing health problems nationally. Weight gain during treatment is the main indicator of good treatment outcome, but there is no adequate information regarding the factors that affect weight gain in Ethiopia.
The objective of this study was to identify determinants of weight gain among adult tuberculosis patients during the intensive phase, in Debre Markos town public health institutions Northwest Ethiopia, 2020.
Unmatched case-control study was conducted in Debre Markos town public health facilities with a total sample size of 236. Cases (clients who got weight) and controls (clients who did not get weight) were enrolled in the study consecutively, and data were collected using standardized questionnaires. Data were entered through Epi-Data version 4.2 and exported to SPSS version 25 for analysis. Bivariable analysis was done, and all independent variables that had < 0.25 were entered into multivariable binary logistic regression analysis. Finally, independent variables which were significantly associated with weight gain at < 0.05 were considered determinant factors of weight gain.
Pulmonary tuberculosis (AOR: 5 (95% CI: 2.3, 11.2)), monitoring by health professionals (AOR: 3.7 (1.6, 8.4)), ≥18.5 baseline body mass index (AOR: 3.4 (95% CI: 1.6, 7.3)), parasitic disease (AOR: 3.2 (95% CI: 1.3, 7.99)), <30 days duration of illness before start of treatment (AOR: 2.8 (95% CI: 1.2, 6.1)), and human immune virus/acquired immune deficiency syndrome (AOR: 3.3 (95% CI: 1.2, 9.1)) were independently associated with weight gain compared to their counterpart.
Type of tuberculosis, monitoring by health professionals, baseline status, parasitic disease, duration of illness before start of treatment, and human immune virus/acquired immune deficiency syndrome were with the determinants of weight gain. Therefore, early detection, support and supervision, and attention for comorbidity are mandatory during antituberculosis treatment.
埃塞俄比亚是全球结核病负担最高的国家之一，结核病是该国最紧迫的健康问题之一。治疗期间体重增加是治疗效果良好的主要指标，但在埃塞俄比亚，关于影响体重增加的因素尚无充分信息。
本研究的目的是确定2020年埃塞俄比亚西北部德布雷马科斯镇公共卫生机构中成年结核病患者强化期体重增加的决定因素。
在德布雷马科斯镇公共卫生设施中进行了非匹配病例对照研究，总样本量为236。病例（体重增加的患者）和对照（体重未增加的患者）连续纳入研究，并使用标准化问卷收集数据。数据通过Epi-Data 4.2版本录入，并导出到SPSS 25版本进行分析。进行了双变量分析，所有P<0.25的自变量都进入多变量二元逻辑回归分析。最后，P<0.05时与体重增加显著相关的自变量被视为体重增加的决定因素。
与对照组相比，肺结核（比值比：5（95%置信区间：2.3，11.2））、卫生专业人员的监测（比值比：3.7（1.6，8.4））≥18.5的基线体重指数（比值比：3.4（95%置信区间：1.6，7.3））、寄生虫病（比值比：3.2（95%置信区间：1.3，7.99））、治疗开始前病程<30天（比值比：2.8（95%置信区间：1.2，6.1））以及人类免疫病毒/获得性免疫缺陷综合征（比值比：3.3（95%置信区间：1.2，9.1））与体重增加独立相关。
结核病类型、卫生专业人员的监测、基线状况、寄生虫病、治疗开始前的病程以及人类免疫病毒/获得性免疫缺陷综合征是体重增加的决定因素。因此，在抗结核治疗期间，早期检测、支持和监督以及对合并症的关注是必不可少的。
